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Individual characteristics, such as smoking habits, viral infection, and occupational and/or environmental factors (such as pesticide exposure), suspected to play a role in lymphoma genesis, have been associated with an increase in t(14;18) translocation frequency. 2 We recently showed that clonotypic t(14;18)-positive cells can persist in the peripheral blood over a long period of time. 3 High t(14;18) rates in HI are mainly because of an expanding population of atypical B cells issued from germinal centre that share genotypic and phenotypic features with FL cells. 4 t(14;18)-positive cells in HI may thus represent much more advanced precursors of the FL pathway than thought earlier.
As t(14;18) in FL, translocation t(11;14)(q13;q32) is considered as the primary event in the pathogenesis of mantle cell lymphoma (MCL), a neoplasia that accounts for 5-10% of all non-Hodgkin's lymphoma. 5 The juxtaposition of the immunoglobulin heavy chain joining region on chromosome 14 to a chromosomal locus on 11q13 places the CCND1/BCL1 gene under the control of the IGH enhancer, resulting in aberrant overexpression of cyclin D1, a positive regulator of the cell cycle. 5 Both t (11;14) and t(14;18) translocations are thought to arise from the same mechanism of illegitimate repair of V(D)J recombination intermediates, with recombinase-mediated breaks in the IGH locus and double-stranded breaks of different origins at the oncogene loci. 6 Considering mechanistic and oncogenic similarities between t(14;18) and t (11;14) , we sought to evaluate the incidence of t (11;14) in HI and their persistence over time. To date, the presence of t(11;14)-positive cells in peripheral blood from HI has only been reported in one individual over the hundred HI studied and at a relatively low frequency (Bsix copies in 1 million normal cells). 7 In this paper, we used a sensitive fluctuation nested PCR analysis to determine the prevalence, frequency and long-term evolution of circulating t(11;14)-positive cells in the peripheral blood of 71 healthy males who had been examined earlier for the t(14;18) translocation using a similar approach. 2, 3 Twenty eight individuals, who were not exposed to pesticides, were issued from a cohort of hospital and laboratory workers and were defined as reference population (mean age at enrolment: 41, min-max: 25-56). 3 Forty three farmers (median age at enrolment: 43, min-max: 27-59) from the EPIBIO97 agricultural cohort, defined as never smoking males and pesticide users on crops at enrolment, were also included. 2 Briefly, fluctuation nested PCR assay was performed on DNA extracted from peripheral blood mononuclear cells (PBMNC) to amplify the IGH/CCND1 der(14) breakpoint (30 replicates per sample) with primers surrounding the BCL1-Major Translocation Cluster (MTC) in combination with JH consensus primers from the IGH locus, and the frequency was estimated using a Poisson's model, as described earlier. 2, 8 The sensitivity of our assay allows us to detect, as few as, one t(11;14)-positive cell in a background of 600 000 normal cells. Sequencing of all PCR products was performed and compared with the GenBank database using BLAST program to identify the CCND1/IGH breakpoint positions and the intervening N region.
For five individuals, two from the reference population (7%) and three farmers (7%), PBMNC samples obtained at enrolment were positive for t (11;14) . Frequencies were at 0.8 and 1.7 translocation copies/10 6 PBMNC ( ). Long-term evolution of t(11;14) could be followed in four HI. t(11;14)-positive PBMNC remained detectable in blood sample up to 9 years after the initial sampling. Frequency varied inside the range of uncertainty in one individual from the reference population and in one farmer, but underwent a threefold and 10-fold increase in the other farmers, reaching 1.7 Â 10 -5 in farmer F272 (Table 1) . Individual R99, for whom four blood samples obtained at intervals of 2-3 years were available, was also included in the follow-up. He was negative at enrolment and 3 years later, whereas t(11;14)-positive cells became detectable in PBMNC obtained at the two latter sampling periods.
All the translocation fragments amplified from the t(11;14)-positive individuals were sequenced (Table 1) . N-nucleotides were present in every case and ranged from 1 to 27 bp in length. Each individual was unique with regard to BCL1 breakpoint, N-nucleotides and J H breakpoint, assuring that no false positive was present. Remarkably, analysis of CCND1/J H junctions showed that the same t(11;14)-positive clone persisted over Table 1 Long-term evolution of frequency and molecular characteristics of t (11;14) Letters to the Editor the overall follow-up period in every individual. Furthermore, the increase in t(11;14) frequency in farmers F272 and F455 could be attributed to the expansion of a unique clone. In one individual, R101, a second clone appeared in the blood sample collected 7 years after enrolment. We show here that circulating t(11;14)-positive cells can be found in HI at a higher prevalence than described earlier, 7 and that their frequency can occasionally go beyond 10 -5 . Based on nucleotide sequence analysis, the translocations found in HI seem indistinguishable from those found in MCL. Particularly striking is the fact that, breakpoints localized in a short region of the major translocation cluster similar to that reported in various series of MCL patients and sometimes occurred at nucleotide positions already reported as breakpoint sites in patients. 8, 9 As long as it can be judged from the small number of CCND1/J H junctions characterized, usage of J H 4 and J H 6 segments seems balanced, resembling more that found in normal B cells or MCL cells, than the biased usage of J H 6 usually observed in t(14;18) from HI and FL patients.
8 J H 4 segment was used in three of the seven CCND1/J H junctions characterized in this study, and only twice among the fifteen different BCL2/J H junctions found in the same HI. The fact that CCND1/J H 1 junctions were found in two individuals is intriguing. Although J H 1 usage is uncommon in a normal V(D)J process, it has been reported in some MCL patients. 9 All these data suggest that t(11;14) translocations found in HI and those found in MCL patients are generated by the same mechanism during illegitimate V(D)J recombination in the bone marrow.
An important finding is the persistence of t(11;14)-positive peripheral blood lymphocytes exhibiting identical CCND1/J H junction, over several years, well beyond the average life span of the normal naive B-lymphocyte pool. This is suggestive of the presence, at least in some HI, of long-lived precursor cells, that are able to form niches and from which circulating cells are recurrently released. Through which process, and in which tissue context, could a B cell bearing the t(11;14) translocation acquire this capacity to survive, proliferate and migrate? t(11;14) translocation in PBMNC from HI places the CCND1 gene in exactly the same molecular context as in MCL cells, and abnormal overexpression of cyclin D1 resulting from CCND1/J H rearrangement is considered the common founding event in the pathogenesis of MCL. Hence, one might envisage that such precursors are B cells frozen at a maturation step corresponding to the putative cellular origin of the tumour. Localized in the mantle zone of activated follicles, MCL recurrently display the CD5 marker, and a fraction of them harbour hypermutations in the IGH variable region. Despite this relatively homogeneous phenotype, 9 the precise physiological counterpart of the tumour remains unclear, 5,10 principally due to the fact that the origin of the cells populating this compartment is still a matter of debate. 11 Further phenotypic and molecular characterization of such long-lived t(11;14)-positive circulating clones in HI might help to decide between the different hypotheses. Why cyclin D1 overexpression becomes a critical perturbation event at such maturation steps is unclear. Blockade of differentiation, extended lifetime, capacity to exit from the follicle to join the bloodstream in search of adequate niches, might also require additional alterations, such as expression of antiapoptotic members of the BCL2 family. 5 This could be part of the reason why t(11;14)-positive PBMNC are only detectable in a few HI.
In two individuals from the group of farmers, an expansion of clonotypic B cells in the circulation, without appearance of new clones, and thus, without any increase of breakage at the CCND1 locus, was observed. This is evocative of a stimulation process associated with exposures to antigens (or more generally to mitogens), whatever the underlying mechanism involved. Our finding can be put together with the experimental observation that transgenic mice expressing D1 in B cells are healthy, and must undergo changes associated with aging to become susceptible to MCL if their immune system is stimulated. 12 It can also be connected with evidences of nonrandom usage of IgVH segments, suggesting that specific antigens may play a pathogenically relevant role in the genesis or progression of subsets of MCL cases. Increased proliferation rates in B cells may indeed render them more susceptible to transformation. 5 Interestingly, five (83%) of the t(11;14)-positive subjects were also positive for t(14;18). The absence of correlation between the frequency and the evolution of the two rearrangements is indicative of different/independent biological behaviours of t(11;14)-positive and t(14;18)-positive cells (Table 1) . Although mechanistically similar, the lower prevalence of t(11;14)-positive individuals as compared with t(14;18)-positive ones might indicate a lower probability of translocation genesis due to a different susceptibility to DNA breakage at the oncogene loci. 6 In addition, differences in clonal expansion propensity and/or in selective advantage conferred by oncogene rearrangement in different immunological environments may explain differences in prevalence. Circulating t(14;18)-positive cells in HI are not naïve mature B cells. Indeed, most of them have undergone immunoglobulin class-switch recombination, which takes place during the germinal centre reaction in response to antigenic stimulation. 4 They likely represent circulating counterparts of frozen GC B cells, capable of responding to stimulus by exogenous antigens and of undergoing clonal expansion. On the other hand, t(11;14)-positive cells may derive from pre-GC B cells at a less advanced stage of maturation with limited expansion and/or with little propensity to recirculate.
The finding of both translocations in the same HI led us to question whether t(14;18)-positive cells could also be detected in the peripheral blood of cyclin D1-positive MCL patients. We found that among three patients at diagnosis, two harboured t(14;18)-positive cells in their peripheral blood. Strikingly, they both displayed surprisingly high frequency of t(14;18) (45 Â 10 -5 ) with several t(14;18)-positive clones in one case. These findings substantiate our earlier proposition that t(14;18) clonal expansion is 'opportunistic', in the sense that it will develop with selective advantage in a proinflammatory and/or protumoral context, independently of cognate antigen-receptor interactions (polyclonal immunological stimulation). 13 Two other MCL patients had received treatment and had disease progression at the time of blood sampling. Interestingly, a t(14;18) could also be found in one of the two patients (although at a relatively low frequency) despite the therapy episode. Although this issue clearly needs to be confirmed on additional cases, this might suggest a particular resistance of t(14;18) precursor clones to conventional therapy. Together with this opportunistic ability of the t(14;18) clones, the concomitant presence of putative early precursors of FL and MCL in some individuals might relate to the occasional occurrence of composite lymphoma reported in the literature. 14 In addition to cyclin D1 deregulation, genomic aberrations are required for complete malignant transformation. 5 The evidence that long-lived CCND1-IGH clones exist in circulating blood and that their frequency can increase with time raises the important question of whether these cells can effectively progress to overt MCL or a subset of this malignancy (including indolent forms). Imatinib mesylate (IM) at 400 mg daily has now become the standard of care for newly diagnosed Philadelphia-positive (Ph þ ) chronic phase-chronic myelogenous leukaemia (CP-CML), and a vast majority of patients show optimal responses translating into high rates of long-term survival. Despite these unprecedented results, up to 23% of patients are reported to discontinue IM treatment, because of an insufficient therapeutic effect. 1 Although a lot of progress has been made for patients showing IM resistance, there is no consensus regarding the management of patients with suboptimal responses. Current options in this setting include continuation of IM at the initial dose, dose escalation of the drug or enrolment into investigational trials. In this study, we retrospectively analyzed the impact of IM dose escalation in 23 newly diagnosed CP-CML patients treated with first-line IM, which showed cytogenetic or primary molecular suboptimal responses as defined by Baccarani et al. 2 It is not clear to date whether these patients need to be considered as primary-resistant to IM or solely insufficient responders for pharmacological reasons, excluding non-compliance.
In suboptimal cytogenetic responders (n ¼ 10), the median duration of IM 400 was 12 months (6-15) and the median follow-up on IM after dose increase was 27 months (10-79) ( Table 1) . We found that IM dose escalation was highly efficient in this setting, leading to a 100% rate of complete cytogenetic response (CCyR: 0% Ph þ ) after a median time of 4 months (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) , that from first intake of IM being 17 months (12) (13) (14) (15) (16) (17) (18) (19) (20) . All patients maintained a stable CCyR while on IM, with a median follow-up after CCyR achievement of 20 months (6-68). Although we cannot completely rule out that some patients may have gained CCyR upon continuation of IM as initially prescribed, our results favourably compared with those derived from the International Randomized Study of Interferon versus STI571 (IRIS) trial, in which the probability of a delayed CCyR in the absence of any therapeutic change was reported in only 46-57% of the patients after 24 months on IM 400. 3 In addition, overall survival and progression-free survival remained similar in patients with a delayed CCyR when compared with patients with CCyR obtained within the first 12 months of treatment.
